Transgenomic CLIA EGFR C797S Mutation Test

Transgenomic has made its EGFR C797S Mutation Detection assay available for clinical use through its CLIA laboratory in Omaha, Nebraska. The test, launched for research use earlier this year and based on the company's ICE COLD-PCR technology, detects the presence of the EGFR C797S mutation associated with resistance to third-generation tyrosine kinase inhibitor therapies for non-small cell lung cancer. It is available as a solo assay and also in three combination panels that include other EGFR mutations, the company said.